Spotlight Center on HIV Prevention Today


3D Imaging Videos Show HIV Infection Might Establish Within Hours

October 26, 2018

A fascinating lecture that generated a lot of discussion at R4P2018 showed how advances in modern scanning technologies including PET scans and light sheet microscopy can be used to get more accurate information about the first stages of HIV infection and on the ways that HIV drugs are absorbed and distributed in the body.

Although this talk used animal studies, the approach is safe enough to use in humans. These might have a role in cure research, for example, to look to measure sites of active HIV replication, before or after a treatment interruption as well as in the development of new drugs.

Many of the videos, which are fascinating to watch, were shown as 3D models -- rotated to view the distributions from any angle -- and then guiding accurate biopsies.


The results looking at HIV transmission in used fluorescent stained proteins to track viral particles in explant tissue or in live animals. One unexpected finding was that virus was transported to mesenteric lymph tissue within hours of infection -- much sooner than genrally assumed. This might have an immediate practical use when modelling PrEP studies.

A second approach, to image drug distribution, can map local absorption of PrEP, for example from a tenofovir vaginal ring, or other topical or system prevention drugs.

As next steps, human imaging that has been discussed for several years is just starting to happen, including in HIV cure research where it has the potential to identify actively productive residual cells.


Hope TJ. Visualizing HIV transmission and prevention. R4P2018, 21-25 October 2018. Plenary lecture abstract PL02.01. (abstract) (webcast)

[Note from TheBodyPRO: This article was originally published by HIV i-Base on Oct. 26, 2018. We have cross-posted it with their permission.]

Related Stories

Longevity of Long-Acting PrEP May Vary Between Men and Women
How to Evaluate PrEP and Vaccines: Urgency for Next-Generation Compounds
Successful Trial of Quadrivalent Mosaic HIV Vaccine Paves Way for Larger Study in Southern Africa

This article was provided by AVAC: Global Advocacy for HIV Prevention. It is a part of the publication 3rd HIV Research for Prevention Conference (R4P2018). Visit AVAC's website to find out more about their activities and publications.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.